RESUMEN
Background: Allergic rhinitis (AR) impacts 10-30% of the world affecting the quality of life of many. Hence, the requirement of a treatment targeted at delivering maximum symptom control and has minimum to no side effects. Objectives: Comparison of efficacy of Bilastine and Fexofenadine in patients suffering from intermittent allergic rhinitis with the help of Total Nasal Symptom Scoring(TNSS) and assessment of side effects- sedation and cardiac toxicity. Methodology: 60 subjects diagnosed with intermittent allergic rhinitis (IAR) were recruited and divided into groups of 30 each. One group was started on Bilastine 20mg OD and the other on Fexofenadine 120mg OD. TNSS was calculated based on symptom severity at presentation, on 10th day and 30th of antihistamine therapy. AEC values and ECG changes were compared for both groups at day 0, day 30. Measurement of sedation was done at day 10, day 30. Intergroup comparison and intragroup assessment of TNSS and its variables, sedative effects and ECG changes at day 0 and day 30 were done using Un-paired and Paired T-test. Results: Patients showed reduction in symptoms of AR with both drugs. TNSS and Rhinorrhoea showed significant improvement in Fexofenadine group as compared to Bilastine. AEC values showed significant reduction in both groups. Statistically significant ECG changes were seen after 30 days of Fexofenadine therapy but were clinically insignificant. No sedative effects were noted with both drugs. Conclusion: Both Bilastine and Fexofenadine were found to be effective in reducing symptoms in patients with IAR. Fexofenadine was more effective than Bilastine in overall symptom control and specifically in controlling rhinorrhoea after one month of therapy. Both the drugs had no sedative effects or cardiac toxicity.
RESUMEN
@#Autoimmune chronic spontaneous urticaria (aiCSU) is characterized by the presence of anti-FceR1 and anti-IgE autoantibodies. In this study we aimed to compare the efficacy and safety of bilastine versus cetirizine in aiCSU.
RESUMEN
Objective: To establish a method for the determination of bilastine in human plasma, and evaluate the uncertainty by LC-MS/MS. Methods: The uncertainty sources were obtained from the whole process of the determination including repeatability, e-quipment error, weighting, solution preparation, calibration fitting and plasma sample handling. The uncertainty and synthesized un-certainty of each component were calculated, and then the expanded uncertainty was obtained. Results: The expanded uncertainty for low (15 ng·ml-1), medium (400 ng·ml-1) and high(1 200 ng·ml-1) level of bilastine was 1. 45 ng·ml-1, 28. 72 ng·ml-1 and 74. 61 ng·ml-1, respectively (k=2, P=95% ). Conclusion: The uncertainty in the determination of bilastine in human plasma is mainly caused by equipment error, solution preparation, protein precipitation and calibration fitting (especially at low level).
RESUMEN
The prevalence of allergic diseases is increasing globally, most particularly in middle- to low-income countries. This article examines the burden of allergic rhinitis and chronic urticaria in the Asia-Pacific region, unmet clinical needs, and the potential role of bilastine in the management of these conditions. An International Advisory Group meeting was convened in association with the Asian Pacific Society of Respirology Annual Congress in November 2014, followed by a literature review, and consensus-based outcomes from the meeting and literature review are described. Regional estimates of the prevalence of allergic rhinitis range from 10% to 50%, while little is known regarding the burden of urticaria in the Asia-Pacific region. A survey of allergy patients in the region identified fast, complete, and long-lasting symptom relief as the medication attributes most important to patients. International treatment guidelines for allergic rhinitis and urticaria advocate the first-line use of second-generation, no-sedating H1-antihistamines, such as bilastine, over their first-generation counterparts and a range of these agents are available to Asia-Pacific patients. The newer agents possess many of the properties of an "ideal" antihistamine (once daily administration, rapid and complete symptom relief, limited potential for drug-drug interactions, minimal side effects). The burgeoning prevalence of allergic diseases in the Asia-Pacific region and the uncontrolled symptoms that these patients experience demand a new antihistamine that offers the highest number of positive features according to the international guidelines.